Multifunctional dendritic cell-targeting polymeric microparticles

References

• Atkinson MA, Eisenbarth GS. Type 1 diabetes: new perspectives on disease pathogenesis and treatment. Lancet 2001; 358:221 - 9
   PubMed Web of Science ®Google Scholar
• Haller MJ, Atkinson MA, Schatz D. Type 1 diabetes mellitus: etiology, presentation and management. Pediatr Clin North Am 2005; 52:1553 - 78
   PubMed Web of Science ®Google Scholar
• bdul-Rasoul M, Habib H, Al-Khouly M. ‘The honeymoon phase in children with type 1 diabetes mellitus: frequency, duration and influential factors. Pediatr Diabetes 2006; 7:101 - 7
   PubMed Web of Science ®Google Scholar
• Lipton R, LaPorte RE, Becker DJ, Dorman JS, Orchard TJ, Atchison J, et al. Cyclosporin therapy for prevention and cure of IDDM. Epidemiological perspective of benefits and risks. Diabetes Care 1990; 13:776 - 84
   PubMed Web of Science ®Google Scholar
• Chatenoud L, Bluestone JA. CD3-specific antibodies: a portal to the treatment of autoimmunity. Nat Rev Immunol 2007; 7:622 - 32
   PubMed Web of Science ®Google Scholar
• Steinman RM, Banchereau J. Taking dendritic cells into medicine. Nature 2007; 449:419 - 26
   PubMed Web of Science ®Google Scholar
• Hilkens CM, Isaacs JD, Thomson AW. Development of dendritic cell-based immunotherapy for autoimmunity. Int Rev Immunol 2010; 29:156 - 83
   PubMed Web of Science ®Google Scholar
• Palucka K, Ueno H, Fay J, Banchereau J. Harnessing dendritic cells to generate cancer vaccines. Ann N Y Acad Sci 2009; 1174:88 - 98
   PubMed Web of Science ®Google Scholar
• http://clinicaltrials.gov/
   Google Scholar
  ClinicalTrials.gov Identifier: NCT00445913; Autologous Dendritic Cell Therapy for Type 1 Diabetes Suppression: A Safety Study 2010.
   Google Scholar
• Phillips B, Nylander K, Harnaha J, Machen J, Lakomy R, Styche A, et al. A microsphere-based vaccine prevents and reverses new-onset autoimmune diabetes. Diabetes 2008; 57:1544 - 55
   PubMed Web of Science ®Google Scholar
• MartIn-Fontecha A, Sebastiani S, Hopken UE, Uguccioni M, Lipp M, Lanzavecchia A, et al. Regulation of dendritic cell migration to the draining lymph node: impact on T lymphocyte traffic and priming. J Exp Med 2003; 198:615 - 21
   PubMed Web of Science ®Google Scholar
• Giannoukakis N, Phillips B, Trucco M. Toward a cure for type 1 diabetes mellitus: diabetes-suppressive dendritic cells and beyond. Pediatr Diabetes 2008; 9:4 - 13
   PubMed Web of Science ®Google Scholar
• Tacken PJ. de V, Torensma RI, Figdor CG. Dendritic-cell immunotherapy: from ex vivo loading to in vivo targeting. Nat Rev Immunol 2007; 7:790 - 802
   PubMed Web of Science ®Google Scholar
• Cohen S, Yoshioka T, Lucarelli M, Hwang LH, Langer R. Controlled delivery systems for proteins based on poly(lactic/glycolic acid) microspheres. Pharm Res 1991; 8:713 - 20
   PubMed Web of Science ®Google Scholar
• Zhao Z, Leong KW. Controlled delivery of antigens and adjuvants in vaccine development. J Pharm Sci 1996; 85:1261 - 70
   PubMed Web of Science ®Google Scholar
• Pean JM, Venier-Julienne MC, Boury F, Menei P, Denizot B, Benoit JP. NGF release from poly(D,L-lactide-co-glycolide) microspheres. Effect of some formulation parameters on encapsulated NGF stability. J Control Release 1998; 56:175 - 87
   PubMed Web of Science ®Google Scholar
• Schaefer MJ, Singh J. Effect of additives on stability of etoposide in PLGA microspheres. Drug Dev Ind Pharm 2001; 27:345 - 50
   PubMed Web of Science ®Google Scholar
• Steinman RM. Dendritic cells in vivo: a key target for a new vaccine science. Immunity 2008; 29:319 - 24
   PubMed Web of Science ®Google Scholar
• Steinman RM, Nussenzweig MC. Dendritic cells: features and functions. Immunol Rev 1980; 53:127 - 47
   PubMed Web of Science ®Google Scholar
• Banchereau J, Briere F, Caux C, Davoust J, Lebecque S, Liu YJ, et al. Immunobiology of dendritic cells. Annu Rev Immunol 2000; 18:767 - 811
   PubMed Web of Science ®Google Scholar
• Steinman RM, Hawiger D, Nussenzweig MC. Tolerogenic dendritic cells. Annu Rev Immunol 2003; 21:685 - 711
   PubMed Web of Science ®Google Scholar
• Morelli AE, Thomson AW. Dendritic cells: regulators of alloimmunity and opportunities for tolerance induction. Immunol Rev 2003; 196:125 - 46
   PubMed Web of Science ®Google Scholar
• Wing K, Sakaguchi S. Regulatory T cells exert checks and balances on self tolerance and autoimmunity. Nat Immunol 2010; 11:7 - 13
   PubMed Web of Science ®Google Scholar
• Mellanby RJ, Thomas DC, Lamb J. Role of regulatory T-cells in autoimmunity. Clin Sci (Lond) 2009; 116:639 - 49
   PubMed Web of Science ®Google Scholar
• Adler HS, Steinbrink K. Tolerogenic dendritic cells in health and disease: friend and foe!. Eur J Dermatol 2007; 17:476 - 91
   PubMed Web of Science ®Google Scholar
• Adorini L, Penna G. Dendritic cell tolerogenicity: a key mechanism in immunomodulation by vitamin D receptor agonists. Hum Immunol 2009; 70:345 - 52
   PubMed Web of Science ®Google Scholar
• Chang CC, Ciubotariu R, Manavalan JS, Yuan J, Colovai AI, Piazza F, et al. Tolerization of dendritic cells by T(S) cells: the crucial role of inhibitory receptors ILT3 and ILT4. Nat Immunol 2002; 3:237 - 43
   PubMed Web of Science ®Google Scholar
• Keir ME, Francisco LM, Sharpe AH. PD-1 and its ligands in T-cell immunity. Curr Opin Immunol 2007; 19:309 - 14
   PubMed Web of Science ®Google Scholar
• Huang L, Baban B, Johnson BA III, Mellor AL. Dendritic cells, indoleamine 2,3 dioxygenase and acquired immune privilege. Int Rev Immunol 2010; 29:133 - 55
   PubMed Web of Science ®Google Scholar
• Singh M, Chakrapani A, O’Hagan D. Nanoparticles and microparticles as vaccine-delivery systems. Expert Rev Vaccines 2007; 6:797 - 808
   PubMed Web of Science ®Google Scholar
• Shi Y, Huang G. Recent developments of biodegradable and biocompatible materials based micro/nanoparticles for delivering macromolecular therapeutics. Crit Rev Ther Drug Carrier Syst 2009; 26:29 - 84
   PubMed Web of Science ®Google Scholar
• Newman KD, Samuel J, Kwon G. Ovalbumin peptide encapsulated in poly(d,l lactic-co-glycolic acid) microspheres is capable of inducing a T helper type 1 immune response. J Control Release 1998; 54:49 - 59
   PubMed Web of Science ®Google Scholar
• Newman KD, Sosnowski DL, Kwon GS, Samuel J. Delivery of MUC1 mucin peptide by Poly(d,l-lactic-co-glycolic acid) microspheres induces type 1 T helper immune responses. J Pharm Sci 1998; 87:1421 - 7
   PubMed Web of Science ®Google Scholar
• Tamber H, Johansen P, Merkle HP, Gander B. Formulation aspects of biodegradable polymeric microspheres for antigen delivery. Adv Drug Deliv Rev 2005; 57:357 - 76
   PubMed Web of Science ®Google Scholar
• Lutolf MP, Hubbell JA. Synthetic biomaterials as instructive extracellular microenvironments for morphogenesis in tissue engineering. Nat Biotechnol 2005; 23:47 - 55
   PubMed Web of Science ®Google Scholar
• Peppas NA, Langer R. New challenges in biomaterials. Science 1994; 263:1715 - 20
   PubMed Web of Science ®Google Scholar
• Johansen P, Martinez Gomez JM, Gander B. Development of synthetic biodegradable microparticulate vaccines: a roller coaster story. Expert Rev Vaccines 2007; 6:471 - 4
   PubMed Web of Science ®Google Scholar
• Elamanchili P, Diwan M, Cao M, Samuel J. Characterization of poly(D,L-lactic-co-glycolic acid) based nanoparticulate system for enhanced delivery of antigens to dendritic cells. Vaccine 2004; 22:2406 - 12
   PubMed Web of Science ®Google Scholar
• Newman KD, Elamanchili P, Kwon GS, Samuel J. Uptake of poly(D,L-lactic-co-glycolic acid) microspheres by antigen-presenting cells in vivo. J Biomed Mater Res 2002; 60:480 - 6
   PubMed Web of Science ®Google Scholar
• Wang D, Molavi O, Lutsiak ME, Elamanchili P, Kwon GS, Samuel J. Poly(D,L-lactic-co-glycolic acid) microsphere delivery of adenovirus for vaccination. J Pharm Pharm Sci 2007; 10:217 - 30
   PubMed Web of Science ®Google Scholar
• Yoshida M, Mata J, Babensee JE. Effect of poly(lactic-co-glycolic acid) contact on maturation of murine bone marrow-derived dendritic cells. J Biomed Mater Res A 2007; 80:7 - 12
   PubMed Web of Science ®Google Scholar
• Yoshida M, Babensee JE. Molecular aspects of microparticle phagocytosis by dendritic cells. J Biomater Sci Polym Ed 2006; 17:893 - 907
   PubMed Web of Science ®Google Scholar
• Fischer S, Uetz-von AE, Waeckerle-Men Y, Groettrup M, Merkle HP, Gander B. The preservation of phenotype and functionality of dendritic cells upon phagocytosis of polyelectrolyte-coated PLGA microparticles. Biomaterials 2007; 28:994 - 1004
   PubMed Web of Science ®Google Scholar
• Hubbell JA, Thomas SN, Swartz MA. Materials engineering for immunomodulation. Nature 2009; 462:449 - 60
   PubMed Web of Science ®Google Scholar
• Acharya AP, Clare-Salzler MJ, Keselowsky BG. A high-throughput microparticle microarray platform for dendritic cell-targeting vaccines. Biomaterials 2009; 30:4168 - 77
   PubMed Web of Science ®Google Scholar
• Mailander V, Landfester K. Interaction of nanoparticles with cells. Biomacromolecules 2009; 10:2379 - 400
   PubMed Web of Science ®Google Scholar
• Waeckerle-Men Y, Allmen EU, Gander B, Scandella E, Schlosser E, Schmidtke G, et al. Encapsulation of proteins and peptides into biodegradable poly (D,L-lactide-co-glycolide) microspheres prolongs and enhances antigen presentation by human dendritic cells. Vaccine 2006; 24:1847 - 57
   PubMed Web of Science ®Google Scholar
• Waeckerle-Men Y, Gander B, Groettrup M. Delivery of tumor antigens to dendritic cells using biodegradable microspheres. Methods Mol Med 2005; 109:35 - 46
   PubMedGoogle Scholar
• Waeckerle-Men Y, Groettrup M. PLGA microspheres for improved antigen delivery to dendritic cells as cellular vaccines. Adv Drug Deliv Rev 2005; 57:475 - 82
   PubMed Web of Science ®Google Scholar
• Hamishehkar H, Emami J, Najafabadi AR, Gilani K, Minaiyan M, Hassanzadeh K, et al. Pharmacokinetics and pharmacodynamics of controlled release insulin loaded PLGA microcapsules using dry powder inhaler in diabetic rats. Biopharm Drug Dispos 2010; 31:189 - 201
   PubMed Web of Science ®Google Scholar
• Hamishehkar H, Emami J, Najafabadi AR, Gilani K, Minaiyan M, Mahdavi H, et al. The effect of formulation variables on the characteristics of insulin-loaded poly(lactic-co-glycolic acid) microspheres prepared by a single phase oil in oil solvent evaporation method. Colloids Surf B Biointerfaces 2009; 74:340 - 9
   PubMed Web of Science ®Google Scholar
• Sheshala R, Peh KK, Darwis Y. Preparation, characterization, and in vivo evaluation of insulin-loaded PLA-PEG microspheres for controlled parenteral drug delivery. Drug Dev Ind Pharm 2009; 35:1364 - 74
   PubMed Web of Science ®Google Scholar
• Goncharova E, Ryzhikov E, Poryvaev V, Bulychev L, Karpyshev N, Maksyutov A, et al. Intranasal immunization with inactivated tick-borne encephalitis virus and the antigenic peptide 89-119 protects mice against intraperitoneal challenge. Int J Med Microbiol 2006; 296:195 - 201
   PubMed Web of Science ®Google Scholar
• Cui C, Stevens VC, Schwendeman SP. Injectable polymer microspheres enhance immunogenicity of a contraceptive peptide vaccine. Vaccine 2007; 25:500 - 9
   PubMedGoogle Scholar
• Goldberg J, Shrikant P, Mescher MF. In vivo augmentation of tumor-specific CTL responses by class I/peptide antigen complexes on microspheres (large multivalent immunogen). J Immunol 2003; 170:228 - 35
   PubMed Web of Science ®Google Scholar
• Savina A, Amigorena S. Phagocytosis and antigen presentation in dendritic cells. Immunol Rev 2007; 219:143 - 56
   PubMed Web of Science ®Google Scholar
• Gerelchuluun T, Lee YH, Lee YR, Im SA, Song S, Park JS, et al. Dendritic cells process antigens encapsulated in a biodegradable polymer, poly(D,L-lactide-co-glycolide), via an alternate class I MHC processing pathway. Arch Pharm Res 2007; 30:1440 - 6
   PubMed Web of Science ®Google Scholar
• Shen H, Ackerman AL, Cody V, Giodini A, Hinson ER, Cresswell P, et al. Enhanced and prolonged cross-presentation following endosomal escape of exogenous antigens encapsulated in biodegradable nanoparticles. Immunology 2006; 117:78 - 88
   PubMed Web of Science ®Google Scholar
• Jones KS. Biomaterials as vaccine adjuvants. Biotechnol Prog 2008; 24:807 - 14
   PubMed Web of Science ®Google Scholar
• Men Y, Audran R, Thomasin C, Eberl G, Demotz S, Merkle HP, et al. MHC class I- and class II-restricted processing and presentation of microencapsulated antigens. Vaccine 1999; 17:1047 - 56
   PubMed Web of Science ®Google Scholar
• Heit A, Schmitz F, Haas T, Busch DH, Wagner H. Antigen co-encapsulated with adjuvants efficiently drive protective T cell immunity. Eur J Immunol 2007; 37:2063 - 74
   PubMed Web of Science ®Google Scholar
• Gerelchuluun T, Lee YH, Lee YR, Im SA, Song S, Park JS, et al. Dendritic cells process antigens encapsulated in a biodegradable polymer, poly(D,L-lactide-co-glycolide), via an alternate class I MHC processing pathway. Arch Pharm Res 2007; 30:1440 - 6
   PubMed Web of Science ®Google Scholar
• Shen Z, Reznikoff G, Dranoff G, Rock KL. Cloned dendritic cells can present exogenous antigens on both MHC class I and class II molecules. J Immunol 1997; 158:2723 - 30
   PubMed Web of Science ®Google Scholar
• Newman KD, Kwon GS, Miller GG, Chlumecky V, Samuel J. Cytoplasmic delivery of a macromolecular fluorescent probe by poly(d, l-lactic-co-glycolic acid) microspheres. J Biomed Mater Res 2000; 50:591 - 7
   PubMed Web of Science ®Google Scholar
• Caputo A, Sparnacci K, Ensoli B, Tondelli L. Functional polymeric nano/microparticles for surface adsorption and delivery of protein and DNA vaccines. Curr Drug Deliv 2008; 5:230 - 42
   PubMedGoogle Scholar
• Lewis KJ, Irwin WJ, Akhtar S. Development of a sustained-release biodegradable polymer delivery system for site-specific delivery of oligonucleotides: characterization of P(LA-GA) copolymer microspheres in vitro. J Drug Target 1998; 5:291 - 302
   PubMed Web of Science ®Google Scholar
• Singh A, Nie H, Ghosn B, Qin H, Kwak LW, Roy K. Efficient modulation of T-cell response by dual-mode, single-carrier delivery of cytokine-targeted siRNA and DNA vaccine to antigen-presenting cells. Mol Ther 2008; 16:2011 - 21
   PubMed Web of Science ®Google Scholar
• Kutzler MA, Weiner DB. DNA vaccines: ready for prime time?. Nat Rev Genet 2008; 9:776 - 88
   PubMed Web of Science ®Google Scholar
• Steinman L. Inverse vaccination, the opposite of Jenner’s concept, for therapy of autoimmunity. J Intern Med 2010; 267:441 - 51
   PubMed Web of Science ®Google Scholar
• Jechlinger W. Optimization and delivery of plasmid DNA for vaccination. Expert Rev Vaccines 2006; 5:803 - 25
   PubMed Web of Science ®Google Scholar
• Wagstaff KM, Jans DA. Nucleocytoplasmic transport of DNA: enhancing non-viral gene transfer. Biochem J 2007; 406:185 - 202
   PubMed Web of Science ®Google Scholar
• Jiang W, Gupta RK, Deshpande MC, Schwendeman SP. Biodegradable poly(lactic-co-glycolic acid) microparticles for injectable delivery of vaccine antigens. Adv Drug Deliv Rev 2005; 57:391 - 410
   PubMed Web of Science ®Google Scholar
• Bramwell VW, Perrie Y. Particulate delivery systems for vaccines: what can we expect?. J Pharm Pharmacol 2006; 58:717 - 28
   PubMed Web of Science ®Google Scholar
• Son S, Lee WR, Joung YK, Kwon MH, Kim YS, Park KD. Optimized stability retention of a monoclonal antibody in the PLGA nanoparticles. Int J Pharm 2009; 368:178 - 85
   PubMed Web of Science ®Google Scholar
• Critchfield JM, Racke MK, Zuniga-Pflucker JC, Cannella B, Raine CS, Goverman J, et al. T cell deletion in high antigen dose therapy of autoimmune encephalomyelitis. Science 1994; 263:1139 - 43
   PubMed Web of Science ®Google Scholar
• Kurts C, Sutherland RM, Davey G, Li M, Lew AM, Blanas E, et al. CD8 T cell ignorance or tolerance to islet antigens depends on antigen dose. Proc Natl Acad Sci USA 1999; 96:12703 - 7
   PubMed Web of Science ®Google Scholar
• Lim DG, Hollsberg P, Hafler DA. Strength of prior stimuli determines the magnitude of secondary responsiveness in CD8+ T cells. Cell Immunol 2002; 217:36 - 46
   PubMed Web of Science ®Google Scholar
• Firpo EJ, Kong RK, Zhou Q, Rudensky AY, Roberts JM, Franza BR. Antigen-specific dose-dependent system for the study of an inheritable and reversible phenotype in mouse CD4+ T cells. Immunology 2002; 107:480 - 8
   PubMed Web of Science ®Google Scholar
• Piaggio E, Hartemann-Heurtier A, Cabarrocas J, Desbois S, Mars LT, Zappulla JP, et al. Maintaining or breaking CD8+ T-cell tolerance to beta islet cell antigens: lessons from transgenic mouse models. J Autoimmun 2004; 22:115 - 20
   PubMed Web of Science ®Google Scholar
• Ertl HC, Varga I, Xiang ZQ, Kaiser K, Stephens L, Otvos L Jr.. Poly (DL-lactide-co-glycolide) microspheres as carriers for peptide vaccines. Vaccine 1996; 14:879 - 85
   PubMed Web of Science ®Google Scholar
• Coombes AG, Lavelle EC, Jenkins PG, Davis SS. Single dose, polymeric, microparticle-based vaccines: the influence of formulation conditions on the magnitude and duration of the immune response to a protein antigen. Vaccine 1996; 14:1429 - 38
   PubMed Web of Science ®Google Scholar
• Yang TC, Millar J, Groves T, Grinshtein N, Parsons R, Takenaka S, et al. The CD8+ T cell population elicited by recombinant adenovirus displays a novel partially exhausted phenotype associated with prolonged antigen presentation that nonetheless provides long-term immunity. J Immunol 2006; 176:200 - 10
   PubMed Web of Science ®Google Scholar
• Strobel S. Immunity induced after a feed of antigen during early life: oral tolerance v. sensitisation. Proc Nutr Soc 2001; 60:437 - 42
   PubMed Web of Science ®Google Scholar
• Reddy ST, Swartz MA, Hubbell JA. Targeting dendritic cells with biomaterials: developing the next generation of vaccines. Trends Immunol 2006; 27:573 - 9
   PubMed Web of Science ®Google Scholar
• Jilek S, Ulrich M, Merkle HP, Walter E. Composition and surface charge of DNA-loaded microparticles determine maturation and cytokine secretion in human dendritic cells. Pharm Res 2004; 21:1240 - 7
   PubMed Web of Science ®Google Scholar
• Kwon YJ, James E, Shastri N, Frechet JM. In vivo targeting of dendritic cells for activation of cellular immunity using vaccine carriers based on pH-responsive microparticles. Proc Natl Acad Sci USA 2005; 102:18264 - 8
   PubMed Web of Science ®Google Scholar
• Heffernan MJ, Kasturi SP, Yang SC, Pulendran B, Murthy N. The stimulation of CD8+ T cells by dendritic cells pulsed with polyketal microparticles containing ion-paired protein antigen and poly(inosinic acid)-poly(cytidylic acid). Biomaterials 2009; 30:910 - 8
   PubMed Web of Science ®Google Scholar
• Wang C, Ge Q, Ting D, Nguyen D, Shen HR, Chen J, et al. Molecularly engineered poly(ortho ester) microspheres for enhanced delivery of DNA vaccines. Nat Mater 2004; 3:190 - 6
   PubMed Web of Science ®Google Scholar
• Watts C. Phagosome neutrality in host defense. Cell 2006; 126:17 - 9
   PubMed Web of Science ®Google Scholar
• Lee S, Yang SC, Heffernan MJ, Taylor WR, Murthy N. Polyketal microparticles: a new delivery vehicle for superoxide dismutase. Bioconjug Chem 2007; 18:4 - 7
   PubMed Web of Science ®Google Scholar
• Cerritelli S, Velluto D, Hubbell JA. PEG-SS-PPS: reduction-sensitive disulfide block copolymer vesicles for intracellular drug delivery. Biomacromolecules 2007; 8:1966 - 72
   PubMed Web of Science ®Google Scholar
• Reddy ST, van’d V, Simeoni E, Angeli V, Randolph GJ, O’Neil CP, et al. Exploiting lymphatic transport and complement activation in nanoparticle vaccines. Nat Biotechnol 2007; 25:1159 - 64
   PubMed Web of Science ®Google Scholar
• Flanary S, Hoffman AS, Stayton PS. Antigen delivery with poly(propylacrylic acid) conjugation enhances MHC-1 presentation and T-cell activation. Bioconjug Chem 2009; 20:241 - 8
   PubMed Web of Science ®Google Scholar
• Swartz MA, Hubbell JA, Reddy ST. Lymphatic drainage function and its immunological implications: from dendritic cell homing to vaccine design. Semin Immunol 2008; 20:147 - 56
   PubMed Web of Science ®Google Scholar
• Reddy ST, Rehor A, Schmoekel HG, Hubbell JA, Swartz MA. In vivo targeting of dendritic cells in lymph nodes with poly(propylene sulfide) nanoparticles. J Control Release 2006; 112:26 - 34
   PubMed Web of Science ®Google Scholar
• Fifis T, Gamvrellis A, Crimeen-Irwin B, Pietersz GA, Li J, Mottram PL, et al. Size-dependent immunogenicity: therapeutic and protective properties of nano-vaccines against tumors. J Immunol 2004; 173:3148 - 54
   PubMed Web of Science ®Google Scholar
• Uchida T, Goto S. Oral delivery of poly(lactide-co-glycolide) microspheres containing ovalbumin as vaccine formulation: particle size study. Biol Pharm Bull 1994; 17:1272 - 6
   PubMed Web of Science ®Google Scholar
• Cruz LJ, Tacken PJ, Fokkink R, Joosten B, Stuart MC, Albericio F, et al. Targeted PLGA nano- but not microparticles specifically deliver antigen to human dendritic cells via DC-SIGN in vitro. J Control Release 2010;
   PubMed Web of Science ®Google Scholar
• Reis e Sousa. Germain RN. Major histocompatibility complex class I presentation of peptides derived from soluble exogenous antigen by a subset of cells engaged in phagocytosis. J Exp Med 1995; 182:841 - 51
   PubMed Web of Science ®Google Scholar
• Bonifaz LC, Bonnyay DP, Charalambous A, Darguste DI, Fujii S, Soares H, et al. In vivo targeting of antigens to maturing dendritic cells via the DEC-205 receptor improves T cell vaccination. J Exp Med 2004; 199:815 - 24
   PubMed Web of Science ®Google Scholar
• Hawiger D, Inaba K, Dorsett Y, Guo M, Mahnke K, Rivera M, et al. Dendritic cells induce peripheral T cell unresponsiveness under steady state conditions in vivo. J Exp Med 2001; 194:769 - 79
   PubMed Web of Science ®Google Scholar
• Lutz MB, Kurts C. Induction of peripheral CD4+ T-cell tolerance and CD8+ T-cell cross-tolerance by dendritic cells. Eur J Immunol 2009; 39:2325 - 30
   PubMed Web of Science ®Google Scholar
• Jiang W, Swiggard WJ, Heufler C, Peng M, Mirza A, Steinman RM, et al. The receptor DEC-205 expressed by dendritic cells and thymic epithelial cells is involved in antigen processing. Nature 1995; 375:151 - 5
   PubMed Web of Science ®Google Scholar
• Trumpfheller C, Finke JS, Lopez CB, Moran TM, Moltedo B, Soares H, et al. Intensified and protective CD4+ T cell immunity in mice with anti-dendritic cell HIV gag fusion antibody vaccine. J Exp Med 2006; 203:607 - 17
   PubMed Web of Science ®Google Scholar
• Soares H, Waechter H, Glaichenhaus N, Mougneau E, Yagita H, Mizenina O, et al. A subset of dendritic cells induces CD4+ T cells to produce IFNgamma by an IL-12-independent but CD70-dependent mechanism in vivo. J Exp Med 2007; 204:1095 - 106
   PubMed Web of Science ®Google Scholar
• Suzue K, Young RA. Adjuvant-free hsp70 fusion protein system elicits humoral and cellular immune responses to HIV-1 p24. J Immunol 1996; 156:873 - 9
   PubMed Web of Science ®Google Scholar
• Guermonprez P, Khelef N, Blouin E, Rieu P, Ricciardi-Castagnoli P, Guiso N, et al. The adenylate cyclase toxin of Bordetella pertussis binds to target cells via the alpha(M)beta(2) integrin (CD11b/CD18). J Exp Med 2001; 193:1035 - 44
   PubMed Web of Science ®Google Scholar
• Tacken PJ, Torensma R, Figdor CG. Targeting antigens to dendritic cells in vivo. Immunobiology 2006; 211:599 - 608
   PubMed Web of Science ®Google Scholar
• Zhang L, Tang Y, Akbulut H, Zelterman D, Linton PJ, Deisseroth AB. An adenoviral vector cancer vaccine that delivers a tumor-associated antigen/CD40-ligand fusion protein to dendritic cells. Proc Natl Acad Sci USA 2003; 100:15101 - 6
   PubMed Web of Science ®Google Scholar
• Apostolopoulos V, Pietersz GA, Gordon S, Martinez-Pomares L, McKenzie IF. Aldehyde-mannan antigen complexes target the MHC class I antigen-presentation pathway. Eur J Immunol 2000; 30:1714 - 23
   PubMed Web of Science ®Google Scholar
• Berry JD, Licea A, Popkov M, Cortez X, Fuller R, Elia M, et al. Rapid monoclonal antibody generation via dendritic cell targeting in vivo. Hybrid Hybridomics 2003; 22:23 - 31
   PubMedGoogle Scholar
• Schuurhuis DH, Ioan-Facsinay A, Nagelkerken B, van Schip JJ, Sedlik C, Melief CJ, et al. Antigen-antibody immune complexes empower dendritic cells to efficiently prime specific CD8+ CTL responses in vivo. J Immunol 2002; 168:2240 - 6
   PubMed Web of Science ®Google Scholar
• Kalergis AM, Ravetch JV. Inducing tumor immunity through the selective engagement of activating Fcgamma receptors on dendritic cells. J Exp Med 2002; 195:1653 - 9
   PubMed Web of Science ®Google Scholar
• Ramakrishna V, Treml JF, Vitale L, Connolly JE, O’Neill T, Smith PA, et al. Mannose receptor targeting of tumor antigen pmel17 to human dendritic cells directs anti-melanoma T cell responses via multiple HLA molecules. J Immunol 2004; 172:2845 - 52
   PubMed Web of Science ®Google Scholar
• He LZ, Crocker A, Lee J, Mendoza-Ramirez J, Wang XT, Vitale LA, et al. Antigenic targeting of the human mannose receptor induces tumor immunity. J Immunol 2007; 178:6259 - 67
   PubMed Web of Science ®Google Scholar
• Boscardin SB, Hafalla JC, Masilamani RF, Kamphorst AO, Zebroski HA, Rai U, et al. Antigen targeting to dendritic cells elicits long-lived T cell help for antibody responses. J Exp Med 2006; 203:599 - 606
   PubMed Web of Science ®Google Scholar
• Tacken PJ, de V, Gijzen KI, Joosten B, Wu D, Rother RP, et al. Effective induction of naive and recall T-cell responses by targeting antigen to human dendritic cells via a humanized anti-DC-SIGN antibody. Blood 2005; 106:1278 - 85
   PubMed Web of Science ®Google Scholar
• Engering A, Geijtenbeek TB, van Vliet SJ, Wijers M, van LE, Demaurex N, et al. The dendritic cell-specific adhesion receptor DC-SIGN internalizes antigen for presentation to T cells. J Immunol 2002; 168:2118 - 26
   PubMed Web of Science ®Google Scholar
• Tillman BW, de Gruijl TD, Luykx-de Bakker SA, Scheper RJ, Pinedo HM, Curiel TJ, et al. Maturation of dendritic cells accompanies high-efficiency gene transfer by a CD40-targeted adenoviral vector. J Immunol 1999; 162:6378 - 83
   PubMed Web of Science ®Google Scholar
• Bonifaz L, Bonnyay D, Mahnke K, Rivera M, Nussenzweig MC, Steinman RM. Efficient targeting of protein antigen to the dendritic cell receptor DEC-205 in the steady state leads to antigen presentation on major histocompatibility complex class I products and peripheral CD8+ T cell tolerance. J Exp Med 2002; 196:1627 - 38
   PubMed Web of Science ®Google Scholar
• Mahnke K, Qian Y, Knop J, Enk AH. Induction of CD4+/CD25+ regulatory T cells by targeting of antigens to immature dendritic cells. Blood 2003; 101:4862 - 9
   PubMed Web of Science ®Google Scholar
• Bruder D, Westendorf AM, Hansen W, Prettin S, Gruber AD, Qian Y, et al. On the edge of autoimmunity: T-cell stimulation by steady-state dendritic cells prevents autoimmune diabetes. Diabetes 2005; 54:3395 - 401
   PubMed Web of Science ®Google Scholar
• Mukhopadhaya A, Hanafusa T, Jarchum I, Chen YG, Iwai Y, Serreze DV, et al. Selective delivery of beta cell antigen to dendritic cells in vivo leads to deletion and tolerance of autoreactive CD8+ T cells in NOD mice. Proc Natl Acad Sci USA 2008; 105:6374 - 9
   PubMed Web of Science ®Google Scholar
• Nimmerjahn F, Ravetch JV. Fcgamma receptors: old friends and new family members. Immunity 2006; 24:19 - 28
   PubMed Web of Science ®Google Scholar
• Ravetch JV, Lanier LL. Immune inhibitory receptors. Science 2000; 290:84 - 9
   PubMed Web of Science ®Google Scholar
• Yamazaki S, Dudziak D, Heidkamp GF, Fiorese C, Bonito AJ, Inaba K, et al. CD8+ CD205+ splenic dendritic cells are specialized to induce Foxp3+ regulatory T cells. J Immunol 2008; 181:6923 - 33
   PubMed Web of Science ®Google Scholar
• Fujikado N, Saijo S, Yonezawa T, Shimamori K, Ishii A, Sugai S, et al. Dcir deficiency causes development of autoimmune diseases in mice due to excess expansion of dendritic cells. Nat Med 2008; 14:176 - 80
   PubMed Web of Science ®Google Scholar
• Wattendorf U, Coullerez G, Voros J, Textor M, Merkle HP. Mannose-based molecular patterns on stealth microspheres for receptor-specific targeting of human antigen-presenting cells. Langmuir 2008; 24:11790 - 802
   PubMed Web of Science ®Google Scholar
• Faraasen S, Voros J, Csucs G, Textor M, Merkle HP, Walter E. Ligand-specific targeting of microspheres to phagocytes by surface modification with poly(L-lysine)-grafted poly(ethylene glycol) conjugate. Pharm Res 2003; 20:237 - 46
   PubMed Web of Science ®Google Scholar
• Kempf M, Mandal B, Jilek S, Thiele L, Voros J, Textor M, et al. Improved stimulation of human dendritic cells by receptor engagement with surface-modified microparticles. J Drug Target 2003; 11:11 - 8
   PubMed Web of Science ®Google Scholar
• Regner M, Martinez X, Belnoue E, Sun CM, Boisgerault F, Lambert PH, et al. Partial activation of neonatal CD11c+ dendritic cells and induction of adult-like CD8+ cytotoxic T cell responses by synthetic microspheres. J Immunol 2004; 173:2669 - 74
   PubMed Web of Science ®Google Scholar
• Acharya AP, Dolgova NV, Clare-Salzler MJ, Keselowsky BG. Adhesive substrate-modulation of adaptive immune responses. Biomaterials 2008; 29:4736 - 50
   PubMed Web of Science ®Google Scholar
• Acharya AP, Dolgova NV, Xia CQ, Clare-Salzler MJ, Keselowsky BG. Adhesive substrates modulate activation and stimulatory capacity of non-obese diabetic mouse-derived dendritic cells. Acta Biomater 2010; 7:180 - 92
   PubMed Web of Science ®Google Scholar
• Acharya AP, Dolgova NV, Xia CQ, Clare-Salzler MJ, Becker ML, Moore NM, et al. The modulation of dendritic cell integrin binding and activation by RGD-peptide density gradient substrates. Biomaterials 2010; 31:7444 - 54
   PubMed Web of Science ®Google Scholar
• Raghuvanshi RJ, Mistra A, Talwar GP, Levy RJ, Labhasetwar V. Enhanced immune response with a combination of alum and biodegradable nanoparticles containing tetanus toxoid. J Microencapsul 2001; 18:723 - 32
   PubMed Web of Science ®Google Scholar
• Schlosser E, Mueller M, Fischer S, Basta S, Busch DH, Gander B, et al. TLR ligands and antigen need to be coencapsulated into the same biodegradable microsphere for the generation of potent cytotoxic T lymphocyte responses. Vaccine 2008; 26:1626 - 37
   PubMed Web of Science ®Google Scholar
• Vollmer J, Weeratna R, Payette P, Jurk M, Schetter C, Laucht M, et al. Characterization of three CpG oligodeoxynucleotide classes with distinct immunostimulatory activities. Eur J Immunol 2004; 34:251 - 62
   PubMed Web of Science ®Google Scholar
• Elamanchili P, Lutsiak CM, Hamdy S, Diwan M, Samuel J. “Pathogen-mimicking” nanoparticles for vaccine delivery to dendritic cells. J Immunother 2007; 30:378 - 95
   PubMed Web of Science ®Google Scholar
• Hamdy S, Molavi O, Ma Z, Haddadi A, Alshamsan A, Gobti Z, et al. Co-delivery of cancer-associated antigen and Toll-like receptor 4 ligand in PLGA nanoparticles induces potent CD8+ T cell-mediated anti-tumor immunity. Vaccine 2008; 26:5046 - 57
   PubMed Web of Science ®Google Scholar
• Malyala P, Chesko J, Ugozzoli M, Goodsell A, Zhou F, Vajdy M, et al. The potency of the adjuvant, CpG oligos, is enhanced by encapsulation in PLG microparticles. J Pharm Sci 2008; 97:1155 - 64
   PubMed Web of Science ®Google Scholar
• Blander JM, Medzhitov R. Toll-dependent selection of microbial antigens for presentation by dendritic cells. Nature 2006; 440:808 - 12
   PubMed Web of Science ®Google Scholar
• Zhao X, Jain S, Benjamin LH, Gonzalez S, Irvine DJ. Directed cell migration via chemoattractants released from degradable microspheres. Biomaterials 2005; 26:5048 - 63
   PubMed Web of Science ®Google Scholar
• Singh A, Suri S, Roy K. In-situ crosslinking hydrogels for combinatorial delivery of chemokines and siRNA-DNA carrying microparticles to dendritic cells. Biomaterials 2009; 30:5187 - 200
   PubMed Web of Science ®Google Scholar
• Hori Y, Winans AM, Huang CC, Horrigan EM, Irvine DJ. Injectable dendritic cell-carrying alginate gels for immunization and immunotherapy. Biomaterials 2008; 29:3671 - 82
   PubMed Web of Science ®Google Scholar
• Ali OA, Mooney DJ. Sustained GM-CSF and PEI condensed pDNA presentation increases the level and duration of gene expression in dendritic cells. J Control Release 2008; 132:273 - 8
   PubMed Web of Science ®Google Scholar
• Ali OA, Huebsch N, Cao L, Dranoff G, Mooney DJ. Infection-mimicking materials to program dendritic cells in situ. Nat Mater 2009; 8:151 - 8
   PubMed Web of Science ®Google Scholar
• Cheatem D, Ganesh BB, Gangi E, Vasu C, Prabhakar BS. Modulation of dendritic cells using granulocyte-macrophage colony-stimulating factor (GM-CSF) delays type 1 diabetes by enhancing CD4+CD25+ regulatory T cell function. Clin Immunol 2009; 131:260 - 70
   PubMed Web of Science ®Google Scholar
• Jhunjhunwala S, Raimondi G, Thomson AW, Little SR. Delivery of rapamycin to dendritic cells using degradable microparticles. J Control Release 2009; 133:191 - 7
   PubMed Web of Science ®Google Scholar
• Das S, Haddadi A, Veniamin S, Samuel J. Delivery of rapamycin-loaded nanoparticle down regulates ICAM-1 expression and maintains an immunosuppressive profile in human CD34+ progenitor-derived dendritic cells. J Biomed Mater Res A 2008; 85:983 - 92
   PubMed Web of Science ®Google Scholar
• Haddadi A, Elamanchili P, Lavasanifar A, Das S, Shapiro J, Samuel J. Delivery of rapamycin by PLGA nanoparticles enhances its suppressive activity on dendritic cells. J Biomed Mater Res A 2008; 84:885 - 98
   PubMed Web of Science ®Google Scholar
• Jia L, Kovacs JR, Zheng Y, Gawalt ES, Shen H, Meng WS. Attenuated alloreactivity of dendritic cells engineered with surface-modified microspheres carrying a plasmid encoding interleukin-10. Biomaterials 2006; 27:2076 - 82
   PubMed Web of Science ®Google Scholar
• Jia L, Kovacs JR, Zheng Y, Shen H, Gawalt ES, Meng WS. Expansion of Foxp3-expressing regulatory T cells in vitro by dendritic cells modified with polymeric particles carrying a plasmid encoding interleukin-10. Biomaterials 2008; 29:1250 - 61
   PubMed Web of Science ®Google Scholar
• Tsai S, Shameli A, Yamanouchi J, Clemente-Casares X, Wang J, Serra P, et al. Reversal of autoimmunity by boosting memory-like autoregulatory T cells. Immunity 2010; 32:568 - 80
   PubMed Web of Science ®Google Scholar
• Machen J, Harnaha J, Lakomy R, Styche A, Trucco M, Giannoukakis N. Antisense oligonucleotides down-regulating costimulation confer diabetes-preventive properties to nonobese diabetic mouse dendritic cells. J Immunol 2004; 173:4331 - 41
   PubMed Web of Science ®Google Scholar
• Harnaha J, Machen J, Wright M, Lakomy R, Styche A, Trucco M, et al. Interleukin-7 is a survival factor for CD4+ CD25+ T-cells and is expressed by diabetes-suppressive dendritic cells. Diabetes 2006; 55:158 - 70
   PubMed Web of Science ®Google Scholar
• Mandal TK. Inhaled insulin for diabetes mellitus. Am J Health Syst Pharm 2005; 62:1359 - 64
   PubMed Web of Science ®Google Scholar
• Poland GA, Ovsyannikova IG, Jacobson RM, Smith DI. Heterogeneity in vaccine immune response: the role of immunogenetics and the emerging field of vaccinomics. Clin Pharmacol Ther 2007; 82:653 - 64
   PubMed Web of Science ®Google Scholar